NXTS earnings analysis
What we found in NXTS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted portion of Nexentis Technologies’ June 30, 2026 10-Q does not include the income statement, balance sheet, cash flow statement, segment data, or MD&A, so current-period financial trends cannot be assessed. Management reported effective disclosure controls as of June 30, 2026 and stated that incorporating MitoCareX into the control environment did not materially affect internal controls. No quantitative guidance was provided, and the company did not provide Item 1A risk-factor disclosures because it qualifies as a smaller reporting company.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure Controls Deemed Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, according to the filing.
- MitoCareX Controls Integration
- Following the acquisition of MitoCareX, the company included the business within its existing financial reporting and consolidation controls; management stated the inclusion did not materially affect internal controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Risk-Factor Disclosure Omitted
- The company stated in Item 1A that, as a smaller reporting company under Rule 12b-2, it is not required to provide risk-factor disclosures; therefore, this filing provides no updated quantitative risk-factor detail.
- Post-Acquisition Integration
- The MitoCareX acquisition required integration into existing financial reporting and consolidation controls during the period ended June 30, 2026. Although management reported no material control impact, post-acquisition integration remains an execution consideration.
What they said about what is next.
No quantitative guidance or outlook was provided in the extracted 10-Q text.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- Nexentis Technologies reported a significant increase in net loss from continuing operations of $7,447,000 for the three months ended March 31, 2026, compared to $1,116,000 in the prior year, primarily due to a $6.3…
- 10-K · March 31, 2026
- Nexentis completed a strategic re‑orientation during/after the 2025 year: it closed the acquisition of MitoCareX (closed October 20, 2025) making MitoCareX a wholly‑owned subsidiary (100% of fully‑diluted share capital)…
- 10-Q · May 15, 2025
- Q1 2025 showed early commercial traction: revenue rose to $66,000 from $44,000 year‑over‑year and gross profit expanded to $52,000. Operating loss narrowed to $(619,000) versus $(899,000) in Q1 2024, but net loss…
- 10-Q · August 14, 2024
- N2OFF reported six‑month revenue of $60,377 (H1 2023: $157,618) and a H1 net loss attributable to stockholders of $1,557,012 (H1 2023: $2,423,183). Cash and cash equivalents were $4,467,529 at June 30, 2024 and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NXTS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever